NCCN Guidelines for Patients
Pancreatic Cancer, Version 1.2014
Locally advanced unresectable pancreatic cancer
If you have a good health status,
then there are
several first-line treatment options to choose from.
The preferred option is to receive treatment within
a clinical trial. A clinical trial is a type of research
that studies the safety and effectiveness of a test or
treatment. (Read page 30 for details on clinical trials.)
Your other options are chemotherapy drugs that have
been tested in clinical trials.
The other options include FOLFIRINOX, gemcitabine
alone, gemcitabine with nab-paclitaxel, a different
gemcitabine-based combination regimen,
capecitabine, or continuous infusion 5-FU.
FOLFIRINOX is a combination regimen that includes
5-FU, leucovorin, irinotecan, and oxaliplatin. (Read
Part 3 on page 28 for treatment details.) Following
any of these chemotherapy options, you may receive
chemoradiation if there is no cancer growth for
months and no signs of distant metastases.
If you have a poor health status,
there are two
treatment options to choose from. One option is
to receive gemcitabine alone. The other option is
to receive the best palliative and supportive care
available. Supportive care—also called palliative
care—is treatment for the symptoms and health
conditions caused by pancreatic cancer. Read Part 4
on page 36 for details.
If first-line treatment doesn’t
stop cancer growth, see Chart
5.4.3 for second-line treatment
recommendations. If the cancer
spreads far from the first tumor,
see Part 5.5 for metastatic cancer